PRECIGEN Investors


63rd American Society of Hematology (ASH) Annual Meeting and Exposition

Dec 11, 2021 at 5:30 PM - 7:30 PM EST

An abstract highlighting PRGN-3007 preclinical data (Abstract# 1694) titled, “Preclinical evaluation of PRGN-3007, a non-viral, multigenic, autologous ROR1 UltraCAR-T® cell therapy with novel mechanism of intrinsic PD-1 blockade for treatment of hematological and solid cancers,” was presented as a poster presentation.

Supporting Materials